Np mrd loader

Record Information
Version1.0
Created at2020-11-23 19:42:20 UTC
Updated at2021-08-12 19:52:22 UTC
NP-MRD IDNP0002865
Secondary Accession NumbersNone
Natural Product Identification
Common Name2,3-Dideoxycytidine
Provided ByBMRBBMRB logo
DescriptionZalcitabine, also known as DDC or hivid, belongs to the class of organic compounds known as pyrimidine 2',3'-dideoxyribonucleosides. Pyrimidine 2',3'-dideoxyribonucleosides are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at positions 2 and 3. Zalcitabine is a drug which is used for the treatment of human immunovirus (hiv) infections in conjunction with other antivirals. In humans, zalcitabine is involved in the zalcitabine action pathway. Zalcitabine is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Zalcitabine is formally rated as a possible carcinogen (by IARC 2B) and is also a potentially toxic compound. It was first documented in 1993 (PMID: 8097417). Based on a literature review a significant number of articles have been published on Zalcitabine (PMID: 17984079) (PMID: 7614775) (PMID: 11905988) (PMID: 7727578).
Structure
Thumb
Synonyms
ValueSource
2',3'-DideoxycytidineChEBI
4-Amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-oneChEBI
DDCChEBI
DDCYDChEBI
DideoxycytidineChEBI
HividKegg
ABBR DDCKegg
HIVID rocheHMDB
2',3' DideoxycytidineHMDB
Hoffman-la roche brand OF zalcitabineHMDB
Roche brand OF zalcitabineHMDB
DDC (Antiviral)HMDB
Chemical FormulaC9H13N3O3
Average Mass211.2178 Da
Monoisotopic Mass211.09569 Da
IUPAC Name4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one
Traditional Namezalcitabine
CAS Registry NumberNot Available
SMILES
NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1
InChI Identifier
InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1
InChI KeyWREGKURFCTUGRC-POYBYMJQSA-N
Experimental Spectra
Spectrum TypeDescriptionDepositor EmailDepositor OrganizationDepositorDeposition DateView
1D NMR13C NMR Spectrum (1D, 500 MHz, D2O, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 500 MHz, D2O, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 500 MHz, D2O, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 500 MHz, D2O, experimental)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
Predicted Spectra
Not Available
Chemical Shift Submissions
Not Available
Species
Species of OriginNot Available
Chemical Taxonomy
Description Belongs to the class of organic compounds known as pyrimidine 2',3'-dideoxyribonucleosides. Pyrimidine 2',3'-dideoxyribonucleosides are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at positions 2 and 3.
KingdomOrganic compounds
Super ClassNucleosides, nucleotides, and analogues
ClassPyrimidine nucleosides
Sub ClassPyrimidine 2',3'-dideoxyribonucleosides
Direct ParentPyrimidine 2',3'-dideoxyribonucleosides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Physical Properties
StateNot Available
Experimental Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Predicted Properties
PropertyValueSource
logP-1.3ALOGPS
logP-1.2ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)14.67ChemAxon
pKa (Strongest Basic)0.18ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area88.15 ŲChemAxon
Rotatable Bond Count2ChemAxon
Refractivity52.24 m³·mol⁻¹ChemAxon
Polarizability20.86 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
HMDB IDHMDB0015078
DrugBank IDDB00943
Phenol Explorer Compound IDNot Available
FoodDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID22498
KEGG Compound IDC07207
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkZalcitabine
METLIN IDNot Available
PubChem Compound24066
PDB IDNot Available
ChEBI ID10101
Good Scents IDNot Available
References
General References
  1. Ulrich EL, Akutsu H, Doreleijers JF, Harano Y, Ioannidis YE, Lin J, Livny M, Mading S, Maziuk D, Miller Z, Nakatani E, Schulte CF, Tolmie DE, Kent Wenger R, Yao H, Markley JL: BioMagResBank. Nucleic Acids Res. 2008 Jan;36(Database issue):D402-8. doi: 10.1093/nar/gkm957. Epub 2007 Nov 4. [PubMed:17984079 ]
  2. Devineni D, Gallo JM: Zalcitabine. Clinical pharmacokinetics and efficacy. Clin Pharmacokinet. 1995 May;28(5):351-60. doi: 10.2165/00003088-199528050-00002. [PubMed:7614775 ]
  3. Shelton MJ, O'Donnell AM, Morse GD: Zalcitabine. Ann Pharmacother. 1993 Apr;27(4):480-9. doi: 10.1177/106002809302700416. [PubMed:8097417 ]
  4. Gibbs JE, Thomas SA: The distribution of the anti-HIV drug, 2'3'-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem. 2002 Feb;80(3):392-404. doi: 10.1046/j.0022-3042.2001.00711.x. [PubMed:11905988 ]
  5. Torres RA, Barr MR, McIntyre KI, Thornton JR, Shay WM, Feldman RD, George NJ, Britton DJ: A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease. Int J STD AIDS. 1995 Jan-Feb;6(1):19-26. doi: 10.1177/095646249500600105. [PubMed:7727578 ]